This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.
Gilead (GILD) Collaborates With Yuhan for NASH Candidates
by Zacks Equity Research
Gilead (GILD) collaborates with Korean company Yuhan for the development of NASH treatments.
The Zacks Analyst Blog Highlights: Bristol-Myers, Celgene, Merck, Pfizer and AbbVie
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Bristol-Myers, Celgene, Merck, Pfizer and AbbVie
AbbVie (ABBV) Inks Immunotherapy Deal with Private Biotech
by Zacks Equity Research
AbbVie (ABBV) inks deal with Tizona Therapeutics, to develop and commercialize CD39-targeted therapeutics, including TTX-030, which is a first-in-class antibody for the treatment of cancer.
Pharma Stock Roundup: BMY to Buy CELG for $74B, MRK Gets Rights to NASH Candidate
by Zacks Equity Research
Bristol-Myers (BMY) is spending $74 billion to buy Celgene. Merck (MRK) exercises option to gain rights to a NASH candidate from partner NGM Biopharmaceuticals.
Pfizer Begins Pivotal Study on Alopecia Areata Candidate
by Zacks Equity Research
Pfizer (PFE) initiates a pivotal phase IIb/III study to evaluate JAK3 inhibitor, PF-06651600, for treating moderate to severe alopecia areata.
Will Pfizer's (PFE) Stock Keep Up the Momentum in 2019?
by Zacks Equity Research
Pfizer (PFE) performs better than the industry in 2018 and looks well poised to keep the positive momentum alive in 2019.
AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, AbbVie (ABBV) closed at $92.19, marking a +1.17% move from the previous day.
Will AbbVie (ABBV) Shares Regain Lost Momentum in 2019?
by Zacks Equity Research
Though AbbVie's (ABBV) stock was down this year, it looks well poised for a recovery in 2019.
AbbVie Partners Lupin to Boost Hematological Cancer Pipeline
by Zacks Equity Research
AbbVie (ABBV) enters into partnership with India-based Lupin, gaining exclusive rights to develop and commercialize the latter's investigational MALT1 inhibitors for hematological cancers.
AbbVie (ABBV) Stock Moves -0.89%: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed the most recent trading day at $84.16, moving -0.89% from the previous trading session.
AbbVie (ABBV) Seeks Approval for RA Candidate Upadacitinib
by Zacks Equity Research
AbbVie (ABBV) submits regulatory applications in the United States and EU for upadacitinib, for the treatment of adult patients with moderate to severe rheumatoid arthritis.
Gilead Partners with Scholar Rock for Fibrotic Disease Drugs
by Zacks Equity Research
Gilead Sciences (GILD) collaborates with Scholar Rock Holding Corporation for the development of fibrotic disease candidates.
Lilly's Taltz Outshines Humira in Psoriatic Arthritis Study
by Zacks Equity Research
Eli Lilly's (LLY) Taltz displays superiority over standard of care medicine Humira in a head-to-head study on patients with active psoriatic arthritis.
The Zacks Analyst Blog Highlights: McDonald???s, AbbVie, Altria, Wells Fargo and Disney
by Zacks Equity Research
The Zacks Analyst Blog Highlights: McDonald???s, AbbVie, Altria, Wells Fargo and Disney
AbbVie (ABBV) Stock Moves -0.79%: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed at $84.93 in the latest trading session, marking a -0.79% move from the prior day.
Top Stocks Reports for McDonald's, AbbVie & Altria
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including McDonald's (MCD), AbbVie (ABBV) and Altria (MO).
Gilead Sciences (GILD) Appoints Daniel O'Day as New CEO
by Zacks Equity Research
Gilead Sciences (GILD) names Roche's Daniel O'Day as the company's new Chairman and CEO.
Bristol-Myers to Study Opdivo in Combo With Vedanta's VE800
by Zacks Equity Research
Bristol-Myers (BMY) enters into a collaboration agreement with Vedanta Biosciences to study Opdivo clubbed with the latter's VE800 for treating patients with advanced or metastatic cancers.
AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, AbbVie (ABBV) closed at $87.59, marking a +0.72% move from the previous day.
Amgen (AMGN) Continues to Reward Shareholders, Ups Dividend
by Zacks Equity Research
Amgen (AMGN) hikes its quarterly dividend by 10%.
Pharma Stock Roundup: Glaxo's TESARO Buyout & Horlicks Sale, ASH Cancer Data Updates
by Zacks Equity Research
Glaxo (GSK) to buy TESARO and divest Horlicks brand to Unilever. ASH cancer presentations grab headilines.
AbbVie Halts Rova-T Phase III Second-Line Lung Cancer Study
by Zacks Equity Research
IDMC recommends AbbVie (ABBV) to stop enrolment in a late-stage study on its small cell lung cancer candidate, Rova-T.
Gilead's (GILD) Harvoni and Descovy Get Approval in China
by Zacks Equity Research
Gilead's (GILD) HCV drug Harvoni and HIV cocktail therapy Descovy get approval in China.
J&J's Blood Cancer Drugs Succeed in Label Expansion Studies
by Zacks Equity Research
J&J (JNJ) presents positive data from late-stage studies evaluating its blood cancer drugs, Imbruvica and Darzalex, in the first-line setting at ASH.
Roche Announces Positive Data on Venclexta/Venclyxto at ASH
by Zacks Equity Research
Roche (RHHBY) announces new Venclexta/Venclyxto data that demonstrate deep responses in two of the most common types of leukaemia.